Stealth BioTherapeutics Plans Exit After FDA Sends Mixed Signals
Stealth BioTherapeutics, the biotech equivalent of a cautious cat, is prepping to shut down after receiving what it called 'conflicting' signals from the FDA. It’s like getting a yes, no, maybe so, and ¯\_(ツ)_/¯ all in one letter. Developing a rare disease drug isn’t for the faint of heart, but apparently trying to decode FDA feedback is a full-contact sport. The company said it's making 'contingency plans to close,' proving sometimes the biggest rare disease is surviving bureaucracy without a sequel to your disaster.
Share the Story
(1 of 3)When the FDA's feedback is so confusing even a biotech drug pitcher gives up and says 'plot twist: closing time.' Rare disease drugs? More like rare clarity.
Stealth BioTherapeutics just experienced the classic FDA mixed signal — like getting ghosted on a text but with your company’s life. 'It’s not you, it’s the ambiguous regulatory dance.'
Trying to get FDA approval from Stealth BioTherapeutics must feel like sending a message in a bottle tossed into a bureaucratic Bermuda Triangle—where rare diseases go to wait for clarity that never arrives.
Source: Statnews | Published: 8/5/2025 | Author: Ed Silverman
More Articles in Health
Motorola Razr Flip Phones Finally Told They’re Secure Enough for 2027
KPMG’s Consulting Business Dies Dramatically While Staff Take a Hike
America Tries Staying Cool While Secretly Preparing For Wattocalypse
90-Year-Old Dad Outsources Bathing to Jovial Nigerian and Ghanaian Carers
Woman Ages Backwards in Online Writing Class, Still Loses to 21-Year-Old
Billionaire’s Daughter’s Brain Hemorrhage Detected Belatedly By $299 Ring
Dietitians Unite to Demand We Eat More Beans, Save Humanity from Boredom
Mark Cuban Declares AI Too Empathetic to Replace Doctors, Only Bullshit Jobs Fear
